Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy

Current Medical Research and Opinion

Volumn 23, Issue 2, 2007, Pages 259-270

  Devereux, Richard B ^a,m,n   De Faire, Ulf ^b   Fyhrquist, Frej ^c   Harris, Katherine E ^d   Ibsen, Hans ^e   Kjeldsen, Sverre E ^f   Lederballe Pedersen, Ole ^g   Lindholm, Lars H ^h   Nieminen, Markku S ^c   Omvik, Per ⁱ   Oparil, Suzanne ^j   Wedel, Hans ^k   Hille, Darcy A ^d   Dahlöf, Björn ^l  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d MERCK RESEARCH LABORATORIES   (United States)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g VIBORG HOSPITAL   (Denmark)

^h UMEÅ UNIVERSITY   (Sweden)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^l SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^m WEILL CORNELL MEDICAL CENTER   (United States)

ⁿ Echocardiography Laboratory   (United States)

more..

Author keywords

Angiotensin receptor blockers; Atenolol; Beta blockers; Diuretics; Hypertension; Left ventricular hypertrophy; Losartan

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYPOCHOLESTEROLEMIC AGENT; LOSARTAN; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; DIASTOLE; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; PULSE; SYSTOLE; TREATMENT OUTCOME;

EID: 33847371746     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X162854     Document Type: Article

References (29)

1. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255-64
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
3. Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension. A review. Hypertension 1989;13:I36-44
4. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-45
5. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994;50:272-98
6. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
7. Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-13
8. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
9. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022-31
10. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86
11. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
12. Kato J, Eto T. Diuretics in the LIFE study. Lancet 2004;364:413-14
13. Dahlöf B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997;10:705-13
14. Dahlöf B, Devereux RB, Julius S, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998;32:989-97
15. Data on file. Merck & Co., Inc., Whitehouse Station, New Jersey, USA. http://www.fda.gov/ohrms/dockets/ac/03/slides/3920S1_01_Merck-CORE%20Slides. ppt#306,49,LIFE: Study Therapy. Accessed 11/15/06
16. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
17. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65
18. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-82
19. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16
20. Dahlöf B, Devereux R, Kjeldsen S. Authors' reply. Lancet 2004;364:413-14.
21. Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 2004;43:1047-55
22. Dahlöf B, Zanchetti A, Diez J, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002;20:1855-64
23. Devereux RB, Dahlöf B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456-62
24. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9
25. Ibsen H, Wachtell K, Olsen MH, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004;22:1805-11
26. Olsen MH, Wachtell K, Neland K, et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005;14:177-83
27. Safar ME, O'Rourke MF. Pulse pressure and antihypertensive agents. Hypertension 2005;46:e6
28. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25
29. Fyhrquist F, Devereux R, Kjeldsen S, Dahlöf B. Response. Hypertension 2005;46:e-e7